Indivior
0
0
+€0.00+0% 00:00 Today
Statistics
Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Dividends
0%Dividend Yield
Jul 16
€0.43
Oct 15
€0.16
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A
Earnings
4AugExpected
Q1 2026
Next
0.56
0.65
0.73
0.82
Expected EPS
0.7821205720000001
Actual EPS
N/A
Financials
16.97%Profit Margin
Profitable1.07BRevenue
182.28MNet Income
Analyst Ratings
34.90Average Price Target
The highest estimate is 34.90.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow 2IV.STU. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap38.37B
Johnson & Johnson
JNJ
Mkt Cap618.61B
Alkermes
ALKS
Mkt Cap8.66B
DaVita
DVA
Mkt Cap14.94B
Novartis
NVS
Mkt Cap293.94B
Pfizer
PFE
Mkt Cap137.76B
Abbvie
ABBV
Mkt Cap438.31B
Merck
MRK
Mkt Cap305.12B
Bristol-Myers Squibb
BMY
Mkt Cap117.58B
About
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). The company also offers OPVEE nasal spray for opioid overdose reversal. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Show more...
CEO
Mr. Joseph J. Ciaffoni
Employees
1000
Country
United Kingdom
ISIN
GB00BRS65X63
Listings
0 Comments
Share your thoughts
FAQ
What is Indivior stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Indivior stocks are traded under the ticker 2IV.STU.
When is the next Indivior earnings date?▼
Indivior is going to release the next earnings report on August 04, 2026.
What were Indivior earnings last quarter?▼
2IV.STU earnings for the last quarter are 0.82 EUR per share, whereas the estimation was 0.56 EUR resulting in a +45.45% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Indivior revenue for the last year?▼
Indivior revenue for the last year amounts to 1.07B EUR.
What is Indivior net income for the last year?▼
2IV.STU net income for the last year is 182.28M EUR.
Does Indivior pay dividends?▼
Yes, 2IV.STU dividends are paid annual. The last dividend per share was 0.43 EUR. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Indivior have?▼
As of July 25, 2026, the company has 1,000 employees.
In which sector is Indivior located?▼
Indivior operates in the Health & Wellness sector.
When did Indivior complete a stock split?▼
The last stock split for Indivior was on October 10, 2022 with a ratio of 1:5.
Where is Indivior headquartered?▼
Indivior is headquartered in North Chesterfield, United Kingdom.